NLS Pharmaceutics CMO Resigns; Interim CMO Appointed
Ticker: NCEL · Form: 6-K · Filed: May 31, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | May 31, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-departure, management-change
TL;DR
NLS Pharma CMO out, CSO steps in as interim. No drama cited.
AI Summary
On May 28, 2024, Dr. George Apostol resigned as Chief Medical Officer (CMO) of NLS Pharmaceutics Ltd., with his resignation effective immediately. The company stated that Dr. Apostol's departure was not due to any disagreements or issues related to the company's operations. Dr. Eric Konofal, the Chief Scientific Officer and Co-Founder, will take over as interim CMO.
Why It Matters
The departure of a key executive like the CMO can signal potential shifts in the company's strategic direction or research and development focus.
Risk Assessment
Risk Level: medium — The resignation of a Chief Medical Officer can indicate internal challenges or a change in strategic direction, warranting closer observation.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Dr. George Apostol (person) — Chief Medical Officer (CMO)
- May 28, 2024 (date) — Date of CMO's resignation notification
- Dr. Eric Konofal (person) — Chief Scientific Officer and Co-Founder, interim CMO
FAQ
When was Dr. George Apostol's resignation as CMO of NLS Pharmaceutics Ltd. effective?
Dr. George Apostol's resignation was effective immediately upon his notification on May 28, 2024.
What was the stated reason for Dr. George Apostol's resignation?
The filing states that Dr. Apostol's resignation was not the result of any disagreement with the Registrant, or due to any matter relating to the Registrant's operations, policies or practices.
Who will assume the role of interim CMO at NLS Pharmaceutics Ltd.?
Dr. Eric Konofal, the Chief Scientific Officer and Co-Founder of the Registrant, will assume the role of interim CMO.
What is the filing number for this Report of Foreign Private Issuer?
The Commission File Number is 001-39957.
What is the principal executive office address for NLS Pharmaceutics Ltd.?
The principal executive office is located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 285 words · 1 min read · ~1 pages · Grade level 10.7 · Accepted 2024-05-31 17:00:04
Filing Documents
- ea0207051-6k_nlspharma.htm (6-K) — 10KB
- 0001213900-24-048522.txt ( ) — 11KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: May 31, 2024 By: /s/ Alexander C. Zwyer Name: Alexander C. Zwyer Title: Chief Executive Officer 2